Search research articles
Contact Us
Filters
Showing results (201-210 of 282) with videos related to
Page
of 29
Sort By:
Clinical Genitourinary Cancer
|
February 9, 2022
Establishing metastatic prostate cancer quality indicators using a modified Delphi approach
Jia Zheng, Fanny Sampurno, Daniel J George, et al.
Journal of Hematology & Oncology
|
May 24, 2018
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
Jun Guo, Jie Jin, Mototsugu Oya, et al.
Therapeutic Advances in Medical Oncology
|
April 25, 2022
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
Ciara Conduit, Blossom Mak, Wenjia Qu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 16, 2004
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
Qiyuan Chen, Heather Jackson, Phillip Parente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
Sebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
BJU International
|
July 19, 2018
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017
Edmund Chiong, Declan G Murphy, Hideyuki Akaza, et al.
Clinical Genitourinary Cancer
|
April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium
Martin Zarba, David Maj, Razane El Hajj Chehade, et al.
European Urology Open Science
|
November 13, 2023
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
Enrique Grande, Aristotelis Bamias, Matthew D Galsky, et al.
BJU International
|
June 5, 2014
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial
Maria Pearse, Carol Fraser-Browne, Ian D Davis, et al.
Page
of 29
Search research articles
Search
Showing results (201-210 of 282) with videos related to
Sort By:
Page
of 29
Clinical Genitourinary Cancer
|
February 9, 2022
Establishing metastatic prostate cancer quality indicators using a modified Delphi approach
Jia Zheng, Fanny Sampurno, Daniel J George, et al.
Journal of Hematology & Oncology
|
May 24, 2018
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
Jun Guo, Jie Jin, Mototsugu Oya, et al.
Therapeutic Advances in Medical Oncology
|
April 25, 2022
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
Ciara Conduit, Blossom Mak, Wenjia Qu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 16, 2004
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
Qiyuan Chen, Heather Jackson, Phillip Parente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
Sebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
BJU International
|
July 19, 2018
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017
Edmund Chiong, Declan G Murphy, Hideyuki Akaza, et al.
Clinical Genitourinary Cancer
|
April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium
Martin Zarba, David Maj, Razane El Hajj Chehade, et al.
European Urology Open Science
|
November 13, 2023
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
Enrique Grande, Aristotelis Bamias, Matthew D Galsky, et al.
BJU International
|
June 5, 2014
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial
Maria Pearse, Carol Fraser-Browne, Ian D Davis, et al.
Page
of 29